Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

– Phase 1B portion of Phase 1B/2 study demonstrated preliminary CR/CRi rate of 33%
– Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of AML
HOUSTON, Oct....

Related Keywords

Houston ,Texas ,United States ,Jenene Thomas ,Walter Klemp ,Securities Exchange ,Moleculin Biotech Inc ,Drug Administration ,Nasdaq ,Company Phase ,Linkedin ,Twitter ,Facebook ,Exchange Commission ,Fast Track Status ,Orphan Drug Designation ,Moleculin Biotech ,Chief Executive Officer ,Transcription Modulator ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Markets ,